Patents Represented by Attorney Darrell Fontenot
-
Patent number: 8329167Abstract: The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.Type: GrantFiled: December 20, 2011Date of Patent: December 11, 2012Assignee: SanofiInventors: Detlef Kozian, Matthias Herrmann
-
Patent number: 8318910Abstract: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor ? and uses thereof.Type: GrantFiled: February 15, 2011Date of Patent: November 27, 2012Assignee: SanofiInventors: Daniel Caput, Pascual Ferrara, Patrick Laurent, Natalio Vita
-
Patent number: 8268560Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.Type: GrantFiled: January 24, 2011Date of Patent: September 18, 2012Assignee: Sanofi-Aventis Deutschland GmbHInventors: Eugen Uhlmann, Gerhard Breipohl, David W. Will
-
Patent number: 8211427Abstract: The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.Type: GrantFiled: January 28, 2011Date of Patent: July 3, 2012Assignee: Sanofi-AventisInventors: Detlef Kozian, Matthias Herrmann
-
Patent number: 8173402Abstract: The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20?HSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives.Type: GrantFiled: January 14, 2011Date of Patent: May 8, 2012Assignee: Aventis Pharma S.A.Inventors: Bruno Dumas, Gilles Cauet, Eric Degryse, Tilman Achstetter
-
Patent number: 8114398Abstract: The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.Type: GrantFiled: September 30, 2006Date of Patent: February 14, 2012Assignee: Sanofi-AventisInventors: Detlef Kozian, Matthias Herrmann
-
Patent number: 8017350Abstract: The present invention relates to a method for identification of a chemical compound which modulates the activity of mammalian GPI-PLC wherein a] a mammalian cell is incubated with glimepiride; b] hcDIGs of the cells of a] are prepared; c] the hcDIGs from b] are incubated with a chemical compound; d] the activity of the GPI-PLC from the hcDIGs of c] is determined.Type: GrantFiled: August 14, 2006Date of Patent: September 13, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Guenter Mueller, Wendelin Frick, Rudolf Schneider
-
Patent number: 7928073Abstract: This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4.Type: GrantFiled: July 15, 2005Date of Patent: April 19, 2011Assignee: Sanofi-AventisInventors: Daniel Caput, Pascual Ferrara, Patrick Laurent, Natalio Vita
-
Patent number: 7897346Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.Type: GrantFiled: May 29, 2009Date of Patent: March 1, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Eugen Uhlmann, Gerhard Breipohl, David William Will
-
Patent number: 7888020Abstract: The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject.Type: GrantFiled: August 7, 2007Date of Patent: February 15, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Detlef Kozian, Evi Kostenis, Karl-Ernst Siegler, Martina Jacobs, Sylvain Ricard, Sandrine Mace, Jean-Francois Deleuze
-
Patent number: 7884200Abstract: Provided herein are retroviral vectors for delivering interfering RNA into cells.Type: GrantFiled: October 7, 2009Date of Patent: February 8, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: Dorre Grueneberg, Gerard Bain, Nayantara Kothari
-
Patent number: 7879592Abstract: The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20?HSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives.Type: GrantFiled: July 24, 2001Date of Patent: February 1, 2011Assignee: Aventis Pharma S.A.Inventors: Bruno Dumas, Gilles Cauet, Tilman Achstetter, Eric Degryse
-
Patent number: 7771731Abstract: An isolated, altered fibronectin-binding protein (Fnb) of S. aureus having at least one mutation in an amino acid selected from residues corresponding to Gln103, Gln105, Lys157, Lys503, Lys620, Lys702, Lys762, Gln783 and Gln830 of FnbA of S. aureus strain ATCC49525 is described. Replacement of these reactive residues within the fibronectin-binding protein renders this protein less capable than wild-type Fnb of covalently cross-linking with fibronectin and fibrin. The altered fibronectin-binding protein effectively interferes with adhesion of S. aureus to fibronectin and fibrin, and therefore, an immunogenic composition comprising such altered Fnb exhibits improved immunogenic properties and is safer to use.Type: GrantFiled: May 17, 2005Date of Patent: August 10, 2010Assignee: Wyeth LLCInventors: Yury Vladimirovich Matsuka, Steven Morris Baker, Elizabeth Teremy Anderson
-
Patent number: 7608278Abstract: The present invention provides a method for producing a less-painful immunogenic composition of a hydrophobic protein in a pharmaceutically acceptable carrier suitable for administering to a mammal, comprising the steps of (a) solubilizing said hydrophobic protein with a zwitterionic detergent to make a first composition; (b) altering said first composition, such that the altered composition produces a reduction in pain as measured in the rat footpad model as compared to said first composition.Type: GrantFiled: December 28, 2004Date of Patent: October 27, 2009Assignee: WyethInventors: Susan Kay Hoiseth, Thomas Newell Metcalf, III, Yury Vladimirovich Matsuka, Michael Hagen, Lakshmi Khandke
-
Patent number: 7588920Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: January 23, 2007Date of Patent: September 15, 2009Assignee: WyethInventors: Lynn Doucette-Stamm, David Bush
-
Patent number: 7566776Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: August 6, 2007Date of Patent: July 28, 2009Assignee: WyethInventors: Lynn Doucette-Stamm, David Bush
-
Patent number: 7541038Abstract: Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.Type: GrantFiled: June 2, 2004Date of Patent: June 2, 2009Assignee: Wyeth Holdings CorporationInventors: Gerald Raul Kovacs, Xiaoyan Mo, Nikolaos Vasilakis, Sangeeta Bhargava, Timothy Joseph Zamb, Stephen Alexander Udem
-
Patent number: 7361496Abstract: This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.Type: GrantFiled: August 2, 2000Date of Patent: April 22, 2008Assignee: WyethInventors: David K. Clarke, J. Erik Johnson, Mohinderjit S. Sidhu, Stephen A. Udem
-
Patent number: 7276359Abstract: A lyophilized polynucleotide composition contains at least one polynucleotide and at least one cryoprotectant, wherein the ratio of the polynucleotide to cryoprotectant is from about 0.001 to about 1.0 part by weight polynucleotide per 1.0 part by weight of the cryoprotectant. This composition also contains from about 0.5 weight percent to about (6) weight percent water, based on the total weight of the final lyophilized polynucleotide composition. The polynucleotide composition of this invention is characterized by enhanced stability, in that it retains at least 90% supercoil over a time period of at least (10) days at a temperature of about 37° C. The lyophilized polynucleotide composition also has improved solubility. An improved process for lyophilization of polynucleotides employs a specific primary drying cycle, that results in the above-described stable, lyophilized polynucleotide composition.Type: GrantFiled: March 12, 1999Date of Patent: October 2, 2007Assignee: WyethInventors: Shankar Musunuri, Patrick P. DeLuca
-
Patent number: 7034141Abstract: The invention generally relates to recombinant polynucleotides, positive-strand RNA virus (psRNAV) recombinant expression vectors, and packaging systems. The packaging systems are based on the expression of helper functions by coinfecting recombinant poxvirus vectors comprising recombinant polynucleotides. Methods for obtaining psRNAV replicon particles using these packaging systems are disclosed. Immunogenic compositions and pharmaceutical formulations are provided that comprise replicon particles of the invention. Methods for generating an immune response or producing a pharmaceutical effect are also provided.Type: GrantFiled: August 28, 2001Date of Patent: April 25, 2006Assignee: Wyeth Holdings CorporationInventors: Gerald R. Kovacs, Nikos Vasilakis, Jacek Kowalski, Seema Gangolli, Timothy Zamb